Insmed vs United Therapeutics

Insmed (INSM), health care, and United Therapeutics (UTHR), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Insmed is worth $26.7B on the stock market and United Therapeutics $24.9B: Insmed is valued at 7% more. Insmed's operating margin in its latest fiscal year was -206% and United Therapeutics's 46.9%. Over the past year Insmed's share price has moved -39.1% and United Therapeutics's +23.4%.

Key facts

Insmed market value
$26.7B
United Therapeutics market value
$24.9B
United Therapeutics P/E
22.0
Insmed revenue
$606.4MFY to 2025-12-31
United Therapeutics revenue
$3.2BFY to 2025-12-31
Superinvestors holding both
2

Market values as of .

Insmed vs United Therapeutics: every measure side by side
Measure Insmed United Therapeutics
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$26.7Bhigher$24.9Blower
Revenue$606.4Mlower$3.2Bhigher
Earnings-$1.3Blower$1.3Bhigher
Employees1,664higher1,400lower
Total assets$2.3Blower$7.9Bhigher
Valuation
P/E—22.0
P/S44.1higher7.8lower
P/B36.8higher3.9lower
Dividend yield0.00%0.00%
Profitability
Operating margin-206%lower46.9%higher
Balance sheet
Net assets$739Mlower$7.1Bhigher
Total liabilities$1.5Bhigher$783.8Mlower
Total debt$546.8M—
Cash on hand$510.4Mlower$1.6Bhigher
Price change
Today-0.83%lower-0.64%higher
1 year-39.1%lower+23.4%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio (under "Both": Insmed / United Therapeutics). Who owns INSM · Who owns UTHR

Further comparisons

Learn

Questions and answers

Which is bigger, Insmed or United Therapeutics?

By market value, Insmed is the larger: $26.7B against $24.9B for United Therapeutics. By revenue in its latest fiscal year, United Therapeutics is the larger: $3.2B against $606.4M for Insmed.

Which has the higher operating margin?

United Therapeutics: 46.9%, against -206% for Insmed. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which superinvestors own both Insmed and United Therapeutics?

In their latest 13F filings, Ray Dalio (founder) and Israel Englander hold both.

Cite this page

Funkfolio, “Insmed vs United Therapeutics”, data as of 18 November 2026. https://funkfolio.com/compare/insm-vs-uthr

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.